BiotechTube
Giant Biogene

Giant Biogene

2367.HK
Xi'an, China· Est.

Giant Biogene is a pioneering synthetic biology company focused on the medical aesthetics and skincare markets. Its core technology platform enables the large-scale production of recombinant collagen, a key biomaterial for skin repair and regeneration. The company has successfully commercialized several flagship skincare brands and is expanding its pipeline into advanced medical applications. Its strategic position is underpinned by strong R&D capabilities and a dominant market share in China's recombinant collagen sector.

giantbiogene.com

2367.HK · Stock Price

HKD 29.78-37.67 (-55.85%)
Market Cap: $3.8B

Historical price data

AI Company Overview

Giant Biogene is a pioneering synthetic biology company focused on the medical aesthetics and skincare markets. Its core technology platform enables the large-scale production of recombinant collagen, a key biomaterial for skin repair and regeneration. The company has successfully commercialized several flagship skincare brands and is expanding its pipeline into advanced medical applications. Its strategic position is underpinned by strong R&D capabilities and a dominant market share in China's recombinant collagen sector.

Medical AestheticsDermatologyWound CareOrthopedics

Technology Platform

Proprietary synthetic biology platform for the industrial-scale production of human-like recombinant collagen using engineered microorganisms, enabling the creation of high-purity, safe, and customizable biomaterials.

Funding History

1
IPOUndisclosed

Opportunities

Significant growth opportunities exist in expanding the medical device pipeline (dermal fillers, wound care) into regulated markets, which command higher margins.
International expansion of its skincare brands, particularly in Southeast Asia, and leveraging its platform to develop new recombinant proteins beyond collagen are key strategic avenues for future growth.

Risk Factors

Key risks include regulatory hurdles for new medical products, high dependence on the Chinese consumer market, potential intensification of competition in the synthetic biology space, and the execution risk associated with transitioning from a skincare company to a broader medical technology player.

Competitive Landscape

Giant Biogene is the clear market leader in recombinant collagen in China, competing with traditional animal-collagen suppliers and broad-based skincare/pharma companies. Its main differentiation is its proprietary, scalable production platform and first-mover commercial success, though it faces future competition from other biotech firms developing alternative biomaterials and regenerative therapies.

More companies in China →